



## **Virus-Like Particle (VLP) Vaccines against Emerging Infectious Diseases**

Guest Editor:

**Dr. Gang Ye**

Department of Pharmacology,  
University of Minnesota Twin  
Cities, Saint Paul, MN 55108, USA

Deadline for manuscript  
submissions:

**31 August 2024**

### **Message from the Guest Editor**

Emerging Infectious Diseases (EIDs) have been threatening human and animal health, causing damage to the global economy and the stability of society. Since 1940, many EID events have been reported, such as West Nile fever, Lassa fever, Ebola hemorrhagic fever, AIDS, and flu. In particular, coronavirus has shocked the world three times in the past 20 years, with the SARS strain in 2002, MERS in 2012 and COVID-19 since 2019. One of the most important strategies to prevent/treat EIDs is vaccination. Virus-Like Particle (VLP) based vaccines are a novel strategy to develop effective vaccines and show advantages over conventional vaccines. As subunit vaccines, they are safer than some conventional vaccines. VLPs better represent antigens on their surface, have high immunogenicity, and are capable of inducing both strong humoral and cellular immune responses.

This Special Issue welcomes studies (research articles and brief reports) focused on Virus-Like Particle (VLP) vaccines against emerging infectious diseases, including those caused by viruses, bacteria, parasites, and other pathogens from either humans or animals.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)